Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/91449 
Year of Publication: 
2013
Series/Report no.: 
Texto para Discussão No. 1825
Publisher: 
Instituto de Pesquisa Econômica Aplicada (IPEA), Brasília
Abstract (Translated): 
Brazil has evolved strikingly in the last few years in the area of health assistance and access to medicines by its aging and urbanizing population. The government has also set the health industry - which includes pharmaceutical innovation - as one of its strategic sectors to be developed in the coming years through tailored policies. However, there is still improvement to be made in the area of matching innovation to the epidemiological needs of Brazilian population. This paper reviews the international literature on mechanism design to bring incentives to pharmaceutical innovation without compromising access to medicines at affordable prices to the broader population and then proposes some policies to be implemented by the Brazilian government in this area. A particular issue at stake is the use of the governmental purchasing power to induce innovation by private pharmaceutical companies, as recommended by some recent and incisive international literature and implemented through a couple of international initiatives these days.
Subjects: 
medicines
pharmaceutical R&D
incentives
pull mechanisms
JEL: 
L65
L52
I18
O31
O34
Document Type: 
Working Paper

Files in This Item:
File
Size
762.15 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.